Supernus, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SUPN research report →
Range $43 – $53
Price Chart
About the company
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC.
- CEO
- Jack A. Khattar
- IPO
- 2012
- Employees
- 827
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on SUPN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $6.03B
- P/E
- 7.93
- Fwd P/E
- 9.40
- PEG
- 0.04
- P/S
- 4.39
- P/B
- -57.11
- EV/EBITDA
- 10.97
- Div Yield
- 28.00%
- Gross Margin
- 85.15%
- Op Margin
- 43.67%
- Net Margin
- 32.75%
- ROE
- -352.94%
- ROIC
- 95.41%
Latest fiscal year · YoY change
- Revenue
- $1.24B+4.3%
- Gross Profit
- $993.00M+3.8%
- Op Income
- $265.00M
- Net Income
- $210.00M+10400.0%
- EPS
- $1.68+11025.8%
- OCF Growth
- -175.0%
- FCF Growth
- -1980.0%
- Beta
- 0.52
- RSI (14)
- 38
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Supernus posted record third-quarter revenue, raised 2026 stand-alone guidance, and said its growth products and Indivior merger momentum remain strong.· October 29, 2026
- Q3 total revenue hit a record $226.8 million, up 18% year over year, driven by growth products Qelbree, ZURZUVAE, ONAPGO and GOCOVRI.
- GAAP EPS improved to $0.35 from a loss of $0.80 a year ago, with operating earnings of $21.2 million versus an operating loss of $60.2 million.
- Management raised full-year 2026 stand-alone guidance for revenue and non-GAAP operating earnings ahead of the expected Nov. 2 merger close.
- Qelbree, ZURZUVAE and ONAPGO all showed strong prescription momentum; ONAPGO supply issues were said to be behind them.
- The company reiterated confidence in $125 million of annual merger synergies and expects combined 2027 guidance in February.
Supernus reported third-quarter 2026 total revenue of $226.8 million, up 18% year over year. Q3 revenue included $178.6 million of net product sales, $41.7 million of collaboration revenue from ZURZUVAE, and $6.5 million of royalties, licensing and other revenue. GAAP operating earnings were $21.2 million versus an operating loss of $60.2 million last year; GAAP net earnings were $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or $(0.80) per diluted share. For the first nine months of 2026, total revenue was $653.5 million, with net product sales of $495 million, ZURZUVAE collaboration revenue of $104.7 million, and royalty/licensing/other revenue of $53.8 million. Cash, cash equivalents and marketable securities were about $359 million at Sept. 30, 2026, versus $309 million at Dec. 31, 2025. For full-year 2026 on a stand-alone basis, the company raised guidance to total revenue of $875 million to $900 million from $860 million to $890 million, and non-GAAP operating earnings of $160 million to $180 million from $150 million to $180 million. Management said this guidance would no longer apply if the Indivior merger closes on Nov. 2.
Jack Khattar framed the quarter as evidence of continued momentum across the commercial portfolio, especially the growth products, and said the company is entering a “new chapter” with Indivior. He emphasized the combined portfolio’s scale, future growth runway into the 2030s, and the ability to fund both portfolio expansion and pipeline development. His tone was upbeat and confident, while still noting that near-term focus will be integration and keeping key growth drivers on track.
Tim Dec focused on the quarterly and year-to-date financial improvement and the balance sheet. He highlighted the record $226.8 million of quarterly revenue, GAAP operating earnings of $21.2 million, adjusted operating earnings of $55.2 million, and the $359 million cash position at quarter-end. He also pointed to stronger full-year stand-alone guidance for revenue and non-GAAP operating earnings, and noted that the merger-driven guidance will be replaced once the transaction closes.
Analysts pressed for more color on ZURZUVAE growth, ONAPGO execution, M&A appetite, Qelbree pricing, and margin expansion. Management said ZURZUVAE demand remains strong and supported by a DTC campaign, with more than 43,000 patients treated since launch and continued education efforts for both consumers and providers. On ONAPGO, management said the backlog from the supply issue is cleared, processing has normalized, and form-to-shipment conversion has improved; the current enrollment-form run rate of roughly 400 to 425 per quarter was described as a reasonable assumption. On M&A and margins, Khattar said the company will remain active in business development, but integration will be a top priority after the merger, and he said stand-alone margins would have improved over time if the company remained independent.
The bull case from the call is that Supernus has multiple products with visible growth momentum, with combined growth-product revenue up 43% year over year in the quarter. Management repeatedly described Qelbree, ZURZUVAE and ONAPGO as still early in their runways, and the company raised full-year stand-alone guidance before the merger closes. The expected $125 million in annual merger synergies and the prospect of a larger, cash-generative combined company add another potential catalyst.
The main risks discussed were merger integration, the loss of stand-alone guidance once the Indivior deal closes, and the fact that some products are still working through commercial scale-up. ONAPGO’s form volume had not accelerated dramatically after supply normalization, and management said the product is still in a relaunch phase. Qelbree remains around 1% market share, and management acknowledged that timing and execution around future growth initiatives and pipeline readouts, including SPN-817, remain uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.2%
- Shares Outstanding
- 207.72M
- Float Shares
- 114.74M
of shares held by institutions
340 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SUPN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 11, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 9, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 24, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 23, 22 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 13, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 17, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 1, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | May 28, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 9.96M | ▲ 608.12K |
| Vanguard Group Inc | 6.05M | ▲ 3.75K |
| Millennium Management LLC | 3.85M | ▲ 537.24K |
| Vanguard Portfolio Management LLC | 3.29M | ▼ 19.96K |
| Armistice Capital, LLC | 2.65M | ▲ 750.85K |
| State Street Corp | 2.57M | ▲ 109.31K |
| Vanguard Capital Management LLC | 2.52M | ▲ 5.97K |
| Nomura Asset Management International Inc. | 2.38M | ▲ 341.13K |
| Dimensional Fund Advisors LP | 1.84M | ▼ 235.78K |
| Stephens Investment Management Group LLC | 1.64M | ▲ 152.23K |
| Geode Capital Management, LLC | 1.53M | ▼ 39.19K |
| Loomis Sayles & Co L P | 1.44M | ▼ 40.07K |
Held by 331 ETFs
Biggest fund positions in SUPN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Mottola Frank | other | 154,010 |
| Nov 2, 26 | Mottola Frank | other | 46,203 |
| Nov 2, 26 | Mottola Frank | other | 38,502 |
| Nov 2, 26 | Mottola Frank | other | 33,882 |
| Nov 2, 26 | Mottola Frank | other | 30,802 |
| Nov 2, 26 | Mottola Frank | other | 30,099 |
| Nov 2, 26 | Mottola Frank | other | 27,721 |
| Nov 2, 26 | Mottola Frank | other | 26,181 |
| Nov 2, 26 | Mottola Frank | other | 21,561 |
| Nov 2, 26 | Mottola Frank | other | 20,791 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SUPN coverage
Recent articles, reports, and earnings notes.
No research on SUPN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SUPN report →